Agnus reports Q3 2026 results highlighted by first marketing approvals for BOT+BAL and global investigator support for Robin's Phase 3 study -. Company announcement - FT.com.
Agnus reports Q3 2026 results highlighted by first marketing approvals for BOT+BAL and global investigator support for Robin's Phase 3 study -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in